We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PeptiMimesis secures €1.2M from Cap Innov’Est
News

PeptiMimesis secures €1.2M from Cap Innov’Est

PeptiMimesis secures €1.2M from Cap Innov’Est
News

PeptiMimesis secures €1.2M from Cap Innov’Est

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PeptiMimesis secures €1.2M from Cap Innov’Est"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PeptiMimesis, a biopharma company dedicated to the discovery and development of therapeutic transmembrane peptides, announces the release of the €0.5m ($0.6m) first tranche of a €1.2m ($1.4m) investment made by Cap Innov’Est, a regionally-based seed fund.

The company will use this funding to initiate its research activities on the design and characterization of transmembrane peptides. PeptiMimesis aims to rapidly identify peptide candidates acting on validated targets in oncology, immuno-oncology and autoimmune diseases.

“PeptiMimesis is a very promising start-up company in the Cap Innov’Est portfolio,” said Jean-François Rax, investment director at Cap Innov’Est. "It has a highly experienced team, bringing together the academic founders, with great scientific knowledge in the field, and Domain Therapeutics’ preclinical research expertise and cutting-edge technology. It also signed a collaboration agreement with IPSEN, only 6 months after incorporation. This is the ideal configuration for rapid value creation.”

“We are very pleased to see Cap Innov’Est joining the company to leverage the potential of PeptiMimesis’ platform in the identification of first-in-class therapeutic peptides,” said Marjorie Sidhoum, president of PeptiMimesis. “We welcome follow-on investments to complete this series A and further accelerate the development of this innovative therapeutic strategy.”

Advertisement